Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics, Inc. - Common Stock
(NQ:
FDMT
)
14.54
+0.20 (+1.36%)
Streaming Delayed Price
Updated: 2:24 PM EDT, Sep 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about 4D Molecular Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
↗
May 16, 2026
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage...
Via
MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress
↗
May 07, 2026
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 06, 2025
Via
Benzinga
FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease
↗
November 06, 2025
Via
Stocktwits
Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock
↗
October 21, 2025
Via
Benzinga
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
↗
March 03, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
↗
February 10, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
↗
January 13, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
October 08, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
September 04, 2025
Via
Benzinga
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
↗
September 03, 2025
Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent," he said.
Via
Benzinga
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
↗
August 12, 2025
Via
Benzinga
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
↗
December 18, 2024
Via
Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
↗
November 14, 2024
Via
Benzinga
4dMT Revenue Jumps 200 Percent in Q2
↗
August 11, 2025
Via
The Motley Fool
Topics
Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
↗
August 04, 2025
Via
Benzinga
Unusual volume stocks in Monday's session
↗
August 04, 2025
Unusual volume stocks are being observed in Monday's session.
Via
Chartmill
Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
↗
August 01, 2025
Via
Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
August 01, 2025
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
The market is filled with gapping stocks in Friday's session.
↗
August 01, 2025
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
↗
August 01, 2025
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.
Via
Benzinga
These stocks that are showing activity before the opening bell on Friday.
↗
August 01, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
August 01, 2025
Via
Benzinga
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
August 01, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 31, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
July 31, 2025
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
↗
July 03, 2025
Via
Benzinga
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
↗
February 10, 2025
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
Via
Benzinga
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
December 18, 2024
Via
Benzinga
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
↗
September 19, 2024
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
